Early Stage Clinical Programs
ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. We are initiating a Phase 2 clinical program in models of acute and chronic pain in the first half of 2021.
Highly selective positive allosteric modulators (PAMs) of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders. In our M1 PAM program we are focused on advancing a portfolio of early stage candidates, including our lead candidate which is in early Phase 1 trials.
*The safety and efficacy of these investigational agents have not been established or approved by the FDA.